Peptide safety is a separate beat from drug safety. Most of the case load involves unregulated research peptides — BPC-157, TB-500, GHK-Cu, MOTS-c, semax, epitalon — sold through medspas, peptide clinics, and online vendors with limited or no quality control.
The pattern keeps repeating. State medical boards and the DOJ open enforcement actions against clinics dispensing peptides labeled as research material to patients. Compounding pharmacies receive FDA warning letters for sterile-compounding deficiencies. Independent analyses find dose variability and contamination. The April 2026 Utah indictment of an osteopathic physician for selling 200+ patients misbranded Chinese peptides — including BPC-157 and retatrutide — was the most recent large case.
Stories here track the enforcement actions, contamination reports, and the policy responses. See #safety for FDA-approved drug AE coverage.
STAT News published an April 29 First Opinion piece arguing that the FDA's pending peptide reclassifications — driven by HHS Secretary RFK Jr.'s public enthusiasm for compounds like BPC-157 and GHK-Cu — risk reopening access to inadequately-tested compounds. The op-ed highlights specific safety concerns flagged in the FDA's original 2023 Category 2 designations: immunogenicity, impurities, and the absence of meaningful human clinical data. The piece is positioned as scientific-community pushback ahead of the July 23-24 PCAC meeting that will rule on seven peptides.
An ABC News-syndicated piece featuring emergency physician and medical toxicologist Dr. Stephanie Widmer ran across ABC affiliates including ABC7 San Francisco, ABC11 Raleigh-Durham, ABC7 Los Angeles, ABC7 Chicago, and ABC13 Houston this week. The piece flagged falsified peptide products tested at arsenic levels up to 10× the toxicity limit for injectables, lead contamination, purity ranging from 5–75%, and documented mislabeling. Cited safety concerns include cardiovascular strain, insulin resistance, psychiatric instability, and blood clots. The breadth of the broadcast parallels FOX's syndicated explainer earlier in the week.
Scientific American published a comprehensive April 18 feature examining the self-injection wellness peptide movement, focusing on BPC-157, TB-500, GHK-Cu, KPV, and ipamorelin. The piece notes that only three small pilot studies have looked at BPC-157 in humans, that most evidence is from rodent models, and that consumers are ordering the compounds from overseas — usually from China — while the FDA prepares to review the category at its July advisory panel.
A BioCentury analysis argues the FDA's April 16 decision to convene a July Pharmacy Compounding Advisory Committee meeting on 12 previously restricted peptides reflects HHS Secretary RFK Jr.'s enthusiasm more than scientific evidence. The outlet warns that most of the peptides under review — for conditions spanning ulcerative colitis, wound healing, obesity, insomnia, and neurological disorders — lack robust clinical safety or efficacy data, and that ideology is increasingly shaping agency decisions.
Scientific American reports that the FDA's decision to convene an expert advisory panel — rather than unilaterally reclassifying peptides — signals a more cautious approach than RFK Jr.'s original February pledge suggested. The panel will weigh limited safety data against surging consumer demand and a growing black market for unregulated peptide products.
Australia's Therapeutic Goods Administration warned of rising imports of unapproved peptide products promoted on social media, citing risks including severe allergic reactions, systemic inflammatory response, infection, and organ damage. Named products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 — often supplied as injectables.
Peter Attia devoted a full AMA episode to peptides, building a framework for evaluating any compound based on mechanism, evidence quality, and safety. The episode examines BPC-157, SS-31, melanotan-II, and CJC-1295, addresses grey-market risks, and maps which areas of medicine stand to benefit most.
ProPublica published a major investigation into the FDA's planned reversal on 19 restricted peptides, warning that reclassification under HHS Secretary RFK Jr. could expose consumers to inadequately tested drugs. The Alliance for Pharmacy Compounding acknowledged it knows little about the safety of individual peptides being sold to the public.
NBC News published a major investigation finding that peptides are advertised online for uses far beyond the science — wrinkle reduction, muscle growth, sleep, and libido — with U.S. peptide searches hitting 10.1 million in January 2026. Experts warned that increased accessibility is outpacing safety and efficacy evidence.
Physician-journalist Dhruv Khullar traces the peptide movement from CrossFit communities to mainstream wellness, documenting contamination (lead in BPC-157, endotoxins in TB-500), lack of human trials, and RFK Jr.'s attacks on FDA restrictions.